Effect Of Zinc Sulfate Supplementation On Premenstrual Syndrome And Health-related Quality Of Life: Clinical Randomized Controlled Trial
Notes for this study:
||PSST insomnia. Placebo: before 68.8, after 69.2. Zinc: before 62.1, after 51.7 .
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 142 women with PMS were allocated to either 220 mg of zinc sulfate (50 mg of elemental zinc) or placebo daily from the 16th day of each menstrual cycle to the 2nd day of the next for 3 months.
On the Premenstrual Symptoms Screening Tool, anger/irritability, anxiety/tension, depressed mood, decreased interest in world activities, decreased interest in-home activities, difficulty concentrating, fatigue, insomnia, hypersomnia, feeling overwhelmed, and physical symptoms all improved in the zinc group more than the placebo group, the difference being statistically significant. In contrast, tearfulness wasn't improved. The improvement in work efficiency, relationship with coworkers, relationships with family, social life activities, and home responsibilities were all improved more in the zinc group than the placebo group, the difference being statistically significant. The improvement tended to increase each month, which likely reflects zinc status improving each month.
On the 12-item Short-Form Health Survey Questionnaire, there was a modest improvement for both physical and psychological symptoms which was statistically significant compared with placebo.